Multi-omic Characterization of Pediatric and Adult Patients Undergoing Hematopoietic Stem Cell Transplantation and Advanced Cell Therapies
The study, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna, aims to elucidate the role of gut microbiota in influencing clinical outcomes in both pediatric and adult patients undergoing HCT and CAR-T therapy. Given the increasing recognition of microbiota's impact on treatment efficacy and safety, the findings could lead to the development of microbiota-informed risk stratification tools and personalized therapeutic strategies. This research may enhance patient outcomes and reduce healthcare costs associated with complications from these therapies. The market for microbiome-related interventions is expanding, with potential applications in antibiotic stewardship and microbiota-modulating therapies. Companies focusing on microbiome research and therapies may find strategic partnerships or investment opportunities arising from this study's outcomes.
Indication: Bone Marrow Replaced Via Transplant
Modality: cell therapy
Target: Gut microbiota composition and its interaction with the host immune system in patients undergoing allogeneic hematopoietic stem cell transplantation (HCT) and CAR-T therapy.
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 10, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Gut microbiota composition and its interaction with the host immune system in patients undergoing allogeneic hematopoietic stem cell transplantation (HCT) and CAR-T therapy.
View original source fields
Condition raw: Bone Marrow Replaced Via Transplant
Condition normalized: Bone Marrow Replaced Via Transplant
Modality raw: cell therapy
Modality normalized: cell therapy
Target raw: Gut microbiota composition and its interaction with the host immune system in patients undergoing allogeneic hematopoietic stem cell transplantation (HCT) and CAR-T therapy.
Target normalized: Gut microbiota composition and its interaction with the host immune system in patients undergoing allogeneic hematopoietic stem cell transplantation (HCT) and CAR-T therapy.